Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease
Alexandra J. Lansky, MD, FACC*,
Ricardo A. Costa, MD*,
Michael Mooney, MD, FACC
,
Mark G. Midei, MD, FACC
,
Henry K. Lui, MD, FACC
,
Warren Strickland, MD, FACC||,
Roxana Mehran, MD, FACC*,
Martin B. Leon, MD, FACC*,
Mary E. Russell, MD, FACC¶,
Stephen G. Ellis, MD, FACC#,
Gregg W. Stone, MD, FACC*,* TAXUS-IV Investigators
* Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York
Abbott Northwestern Hospital, Minneapolis, Minnesota
St. Josephs Medical Center Towson, Towson, Maryland
Research Associates of Jackson, Jackson, Tennessee
|| Huntsville Hospital, Huntsville, Alabama
¶ Boston Scientific Corp., Natick, Massachusetts
# The Cleveland Clinic Foundation, Cleveland, Ohio

View larger version (24K):
[in a new window]
|
Figure 1 Multivariate predictors of one-year target lesion revascularization (top) and target vessel revascularization (bottom) in patients randomized to the paclitaxel-eluting stent. CI = confidence interval; HR = hazard ratio.
|
|
Copyright © 2005 by the American College of Cardiology Foundation.